About Polyplus Transfection
Polyplus Transfection is a company based in Illkirch-graffenstaden (France) founded in 2001 was acquired by Sartorius in March 2023. Polyplus Transfection has raised $3.23 million across 2 funding rounds from investors including Sartorius, CIC and Warburg Pincus. Polyplus Transfection has completed 2 acquisitions, including Bio Elpida and Xpress Biologics. Polyplus Transfection offers products and services including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS. Polyplus Transfection operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Illkirch-graffenstaden, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.23 M (USD)
in 2 rounds
-
Latest Funding Round
$3.23 M (USD), Series A
Jan 10, 2011
-
Investors
Sartorius
& 9 more
-
Employee Count
Not available
-
Investments & Acquisitions
Bio Elpida
& 1 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Polyplus Transfection
Polyplus Transfection offers a comprehensive portfolio of products and services, including FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS.
For large scale rAAV manufacturing processes
Leader for viral vector production in various scales
For in vivo mRNA delivery using lipid nanoparticles
For high-yield protein expression in cell systems
For efficient DNA transfection in hard-to-transfect cells
Funding Insights of Polyplus Transfection
Polyplus Transfection has successfully raised a total of $3.23M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.23 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Polyplus Transfection
Polyplus Transfection has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Sartorius, CIC and Warburg Pincus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Polyplus Transfection
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Polyplus Transfection
Polyplus Transfection has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio Elpida and Xpress Biologics.
Investment portfolio details for Polyplus Transfection
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CRO offering recombinant protein and antibody related services for preclinical and clinical applications
|
Locked | Locked | 2014 | Locked | |
|
Bio Elpida, a Biotechnology Contract Manufacturing Company for pre-clinical and clinical development of cell therapy products and bio-products
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Polyplus Transfection
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Polyplus Transfection
Detailed financials for Polyplus Transfection
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Polyplus Transfection Comparisons
Peer comparison for Polyplus Transfection
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Polyplus Transfection
Polyplus Transfection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Polyplus Transfection
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Polyplus Transfection
Complete news archive for Polyplus Transfection
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Polyplus Transfection
Polyplus Transfection was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Polyplus Transfection is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Polyplus Transfection is a funded company, having raised a total of $3.23M across 2 funding rounds to date.
Polyplus Transfection is a biotechnology company that develops and sells innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a global distributor network for use in clinical trials. Also holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery. Products include - jetPRIME, INTERFERin, FectoPRO, PEIpro for in-vitro; in vivo-jetPEI, cGMP grade in vivo-jetPEI, jetSI 10 mM for in vivo; and others like Zip Nucleic acid (ZNA for Molecular Biology Diagnostics), STICKY SIRNA (for Therapeutic siRNA), OLIGOPLUS and SIRNAPLUS (for Therapeutic cationic Oligonucleotides), Personalized transfection services (for Transfection optimization) and Custom-made products (for in vitro transfection, therapeutics).
Polyplus Transfection's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Polyplus Transfection offers FectoVIR, PEIpro, in vivo-jetRNA, FectoPRO, and jetOPTIMUS.
Polyplus Transfection has made 2 acquisitions, including Bio Elpida, and Xpress Biologics.
Polyplus Transfection has 10 investors. Key investors include Sartorius, CIC, Warburg Pincus, Crédit Mutuel Equity, and Banque de Vizille.